Clinical trial

The Genetic Contribution to Progression of Kidney Disease

Name

GenNefro01

Description

This study evaluates the role of genetic in the development and progression of different nephropaties with particular attention to: * AKI * CKD * Hypertension * ADPKD * CKD-MBD * Patients with decompensated heart failure undergoing either medical or surgery therapy * Patients with hematologic cancer exposed to chemotherapeutic agents or undergoing allogeneic bone marrow transplantation * glomerular diseases

Trial arms

Trial start

2006-05-19

Estimated PCD

2040-05-19

Trial end

2041-05-19

Status

Recruiting

Treatment

genetic polymorphisms

Arms:

Patients with acute or chronic nephropathy

Size

10000

Primary endpoint

difference in glomerular filtration rate according to genetic profile

from days to 35 years

Eligibility criteria

Inclusion Criteria: . presence of specific renal disease Exclusion Criteria: * to be evaluated in the different sub-protocols

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'OTHER', 'timePerspective': 'OTHER'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'blood , urine and sample of renal tissue'}, 'enrollmentInfo': {'count': 10000, 'type': 'ESTIMATED'}}

Updated at

2024-05-16

1 organization

1 product

8 indications

Organization

Ospedale San Raffaele

Product

Genetic Polymorphisms

Indication

Acute Kidney Injury

Indication